Context:

Open enrollment for Medicare runs through Dec. 7, with changes taking effect in 2027 as beneficiaries choose between traditional Medicare and Medicare Advantage, plus prescription drug plans. Key shifts include higher Part D out-of-pocket caps and deductibles, the end of temporary premium subsidies, and the start of Medicare drug price negotiations covering 15 drugs. The 2027 adjustments come alongside a 3.6% Social Security cost-of-living adjustment and ongoing political promises affecting retirees, underscoring a period of rising costs and shifting options for seniors. The overall outlook suggests modest price movements for most, while beneficiaries are urged to shop for plans that fit their needs amid inflation and policy changes.

Dive Deeper:

• Open enrollment lasts until December 7, during which individuals can compare traditional Medicare, Medicare Advantage plans, and prescription drug plans, with changes effective January 1.

• For 2027, the annual out-of-pocket cap for Part D drugs rises to $2,400 from $2,100, and the standard deductible increases from $615 to $700, expanding initial cost exposure for enrollees.

• A temporary Part D premium subsidy will end earlier than planned, and the subsidy program established in 2024 under the previous administration is phasing out.

• New Medicare-negotiated prices apply to 15 drugs, including Ozempic, Rybelsus, and Wegovy, and additional medications will be covered starting January 1, as part of a Biden-era pricing framework.

• CMS projects these changes will lower overall prescription drug costs for Medicare participants by about $685 million in 2027, though individual impacts will vary by plan and usage.

• Analysts note inflation and rising healthcare costs are pressuring seniors, with the SSA confirming a 3.6% COLA for 2027 translating to roughly $75 more per month for most beneficiaries, and about 7.3 million SSI recipients gaining similarly.

• In political developments, former President Trump has proposed one-time $90 payments to help cover Part B premiums, costing roughly $2 billion and excluding many groups such as most Medicare Advantage enrollees and low-income beneficiaries.